George Lundberg, MD Editor in Chief at Cancer Commons
-
December 2, 2019
Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial Bookmark
George Lundberg, MDResearch paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes:
This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.
Go to full paper published in Annals of Surgery.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICML Bookmark
George Lundberg, MDContinuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes:
Recent research findings can change practices for B-cell malignancies.
Go to educational module at Clinical Care Options (requires free registration).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Pembrolizumab Plus Lenvatinib Approved for Endometrial Cancer Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Risk of a Second Cancer in Canadians Diagnosed with a First Cancer in Childhood or Adolescence Bookmark
George Lundberg, MDResearch paper from EClinicalMedicine curated by Editor in Chief George Lundberg, MD, who notes:
People who survive after treatment for childhood cancers have a greatly increased likelihood of developing a second cancer, with younger patients at greatest risk.
Go to full paper published in EClinicalMedicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma Bookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers Bookmark
George Lundberg, MDArticle from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes:
In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.
Go to full article published by Targeted Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Ovarian Cancer: Is This the Beginning of the End? Bookmark
George Lundberg, MDArticle from Healio curated by Editor in Chief George Lundberg, MD, who notes:
This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.
Go to full article published by Healio.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Novel, High-Accuracy Blood Test Can Screen for Multiple Cancers Bookmark
George Lundberg, MDArticle from MDLinx curated by Editor in Chief George Lundberg, MD, who notes:
Very early detection of potentially lethal cancer remains an elusive goal. Blood tests that evaluate methylation of cell-free DNA may be one strategy for earlier detection of ovarian cancer and other types of cancer. High sensitivity and specificity are crucial.
Go to full article published by MDLinx.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Scientists Find Promising Drug Combination Against Lethal Childhood Brain Cancers Bookmark
George Lundberg, MDArticle from EurekAlert curated by Editor in Chief George Lundberg, MD, who notes:
Researchers have shown that a combination therapy is effective against cancer cells in test-tube experiments and laboratory animals. It has not yet been tested in humans.
Go to full article published by EurekAlert.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (Attraction-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial Bookmark
George Lundberg, MDResearch paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes:
In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.
Go to full paper published in The Lancet.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.